These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26323873)

  • 1. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
    Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
    Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
    Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
    Chattopadhyay M; Kodela R; Olson KR; Kashfi K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
    Vannini F; Kodela R; Chattopadhyay M; Kashfi K
    Redox Biol; 2015 Aug; 5():421. PubMed ID: 28162291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
    Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
    Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
    Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
    Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
    Kashfi K
    Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders.
    Lee M; McGeer E; Kodela R; Kashfi K; McGeer PL
    Glia; 2013 Oct; 61(10):1724-34. PubMed ID: 23918470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in
    Antoniou C; Xenofontos R; Chatzimichail G; Christou A; Kashfi K; Fotopoulos V
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
    Kashfi K; Borgo S; Williams JL; Chen J; Gao J; Glekas A; Benedini F; Del Soldato P; Rigas B
    J Pharmacol Exp Ther; 2005 Mar; 312(3):978-88. PubMed ID: 15528453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
    Kashfi K; Chattopadhyay M; Kodela R
    Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
    Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
    Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain.
    Fonseca MD; Cunha FQ; Kashfi K; Cunha TM
    Pharmacol Res Perspect; 2015 Jun; 3(3):e00133. PubMed ID: 26236481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.
    Kodela R; Chattopadhyay M; Kashfi K
    ACS Med Chem Lett; 2012 Mar; 3(3):257-262. PubMed ID: 22916316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of nitric oxide-donating aspirin.
    Kashfi K; Rigas B
    Biochem Biophys Res Commun; 2007 Jul; 358(4):1096-101. PubMed ID: 17512900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
    Chattopadhyay M; Kodela R; Nath N; Dastagirzada YM; Velázquez-Martínez CA; Boring D; Kashfi K
    Biochem Pharmacol; 2012 Mar; 83(6):715-22. PubMed ID: 22222427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOSH-aspirin (NBS-1120) inhibits estrogen receptor negative breast cancer
    Chattopadhyay M; Nath N; Kodela R; Metkar S; Soyemi SA; Kashfi K
    J Pharmacol Exp Ther; 2024 Jun; ():. PubMed ID: 38936976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New nitric oxide or hydrogen sulfide releasing aspirins.
    Lazzarato L; Chegaev K; Marini E; Rolando B; Borretto E; Guglielmo S; Joseph S; Di Stilo A; Fruttero R; Gasco A
    J Med Chem; 2011 Aug; 54(15):5478-84. PubMed ID: 21688846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
    Hua A; Mackenzie GG; Rigas B
    Int J Oncol; 2009 Oct; 35(4):837-44. PubMed ID: 19724920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
    Kodela R; Chattopadhyay M; Goswami S; Gan ZY; Rao PP; Nia KV; Velázquez-Martínez CA; Kashfi K
    J Pharmacol Exp Ther; 2013 Apr; 345(1):85-94. PubMed ID: 23349335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.